Overview

Bevacizumab Against Recurrent Retinal Detachment

Status:
Completed

Trial end date:
2019-11-11

Target enrollment:

Participant gender:

Summary

The investigators hypothesize that bevacizumab instilled into the vitreous after primary retinal detachment surgery will reduce the formation of proliferative vitreoretinopathy and subsequent retinal re-detachment.

Phase:

Phase 2

Details

Lead Sponsor:

University of Wisconsin, Madison

Treatments:

Bevacizumab